Embecta Corp. is a healthcare company that focuses on the development and manufacturing of products for people living with diabetes
The company specializes in diabetes management solutions, including insulin delivery systems and other related devices, aimed at improving the quality of life for patients. With a commitment to innovation, Embecta aims to enhance the safety and efficiency of diabetes care, ultimately contributing to better health outcomes for individuals managing this chronic condition. Its comprehensive portfolio is designed to address the diverse needs of users, from novice patients to experienced individuals, ensuring accessible and effective technologies in diabetes therapy.
Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to 30%.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and declining margins.
